EUCTR2008-004467-19-HU进行中（未招募）不适用
An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis, previously enrolled in and having completed ENACT (CAMN107A2109) trial in Hungary.
ovartis Hungary Ltd0 个研究点开始时间: 2008年7月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients under consideration for participation in this study must meet the following inclusion criteria:
- •1.Imatinib - resistant or - intolerant Philadelphia chromosome-positive CML in chronic phase, accelerated phase or in blast crisis patients previously enrolled to CAMN107A2109 in Hungary and continuing the treatment with nilotinib at the time of enrollment for this trial.
- •2.According to the opinion of the investigators the patient would benefit from the further treatment with nilotinib.
- •3.No evidence of extramedullary leukaemic involvement, with the exception of liver and spleen.
- •4.Males or females =18 years of age.
- •5.QTc = 450 msec on the average of three serial baseline ECG (using the QTcF formula).
- •6.Patients must have the following laboratory values:
- •Potassium within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication.
- •Total calcium (corrected for serum albumin) within normal limits or correctable with supplements.
- •Magnesium within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication.
- •Phosphorus = LLN or correctable with supplements.
- •ALT and AST = 2.5 x ULN or = 5.0 x ULN unless considered due to tumour.
- •Alkaline phosphatase = 2.5 x ULN unless considered due to tumour.
- •Serum bilirubin = 1.5 x ULN unless considered due to tumour.
- •Serum creatinine = 1.5 x ULN or 24-hour creatinine clearance = 50 ml/min.
- •Serum amylase = 1.5 x ULN and serum lipase = 1.5 x ULN.
- •9.Written signed and dated informed consent prior to any study procedures being performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known T315I mutations
- •2.Impaired cardiac function including any one of the following:
- •LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by echocardiogram.
- •Inability to determine the QT interval on ECG.
- •Complete left bundle branch block.
- •Use of a ventricular-paced pacemaker.
- •Congenital long QT syndrome or a known family history of long QT syndrome.
- •History of or presence of clinically significant ventricular or atrial tachyarrhythmias.
- •Clinically significant resting brachycardia (< 50 beats per minute).
- •QTc > 450 msec on the average of three serial baseline ECG (using the QTcF formula). If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
- •History of clinically documented myocardial infarction.
- •History of unstable angina (during the last 12 months).
- •Other clinically significant heart disease (e.g. congestive heart failure or uncontrolled hypertension).
- •3.Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)
- •4.Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection)
- •5.History of significant congenital or acquired bleeding disorder unrelated to cancer
- •6.Previous radiotherapy to = 25% of the bone marrow
- •7.Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery
- •8.History of non-compliance to medical regimens or inability to grant consent
- •9.Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)
- •10.Patients actively receiving therapy with strong CYP3A4 inhibitors (e.g, erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm.
- •11.Patients actively receiving therapy with strong CYP3A4 inducers (e.g, dexamthasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John’s Wort) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm.
- •12.Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
- •13.History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
- •14.Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease
- •15.Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. (Please see http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a comprehensive list of agents that prolong the QT interval)
- •16.Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) male or female of childbea
研究者
相似试验
已完成
不适用
A phase I, multicenter, open-label study of oral ABL001 in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic Leukemia (CABL001X2101)chronic myelogenous leukemia/Philadelphia chromosome-positive acute lymphoblastic leukemia10024324leukemiaNL-OMON55523ovartis15
已完成
不适用
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseLeukemia, Myeloid, ChronicNCT00538109King Faisal Specialist Hospital & Research Center8
进行中（未招募）
1 期
A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations.Estudio abierto aleatorio del fármaco oral CEP-701 administrado consecutivamente con quimioterapia estándar en pacientes que han sufrido recaídas de leucemia mieloide aguda (LMA) mostrando mutaciones asociadas a la actividad del FLT-3Relapsed Acute Myeloid Leukaemia (AML) expressing FLT-3 activating mutations.EUCTR2005-002258-23-ESCephalon Inc.120
进行中（未招募）
不适用
A Randomized, Open Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations - NARelapsed Acute Myeloid Leukaemia (AML) expressing FLT-3 activating mutations.MedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaEUCTR2005-002258-23-DECephalon Inc.220
进行中（未招募）
不适用
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating MutationsMedDRA version: 14.1Level: PTClassification code 10059034Term: Acute myeloid leukaemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Acute Myeloid LeukemiaEUCTR2005-002258-23-ITCEPHALON EUROPE220